Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma
In cases of effective management, decreasing the RDI during EV monotherapy does not negatively impact the survival outcomes.
Authors
- Yoriaki Kaneko (ORCID: https://orcid.org/0000-0003-4567-6082)
- Takuo Matsukawa (ORCID: https://orcid.org/0009-0009-4418-399X)
- Eiji Kashiwagi (ORCID: https://orcid.org/0000-0001-9424-3764)
- Yui Mizushima
- Ikko Tomisaki (ORCID: https://orcid.org/0000-0002-7818-0780)
- Akinori Minato (ORCID: https://orcid.org/0000-0001-6303-1128)
- Yujiro Nagata (ORCID: https://orcid.org/0000-0001-6815-4266)
- Toshinobu Tanaka
- TOMEI SUGI
- Yoshihiro Sugita
- Katsuyoshi Higashijima
- K. Jojima
- T Takaba
- Tadashi Bando
- Ryota Hongyo
Institutions
- University of Occupational and Environmental Health Japan (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1093/jjco/hyaf049
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01